Pharmaceutical

Indian regulator CDSCO has granted marketing approval to Servier India for a novel brain-cancer drug — a development that could significantly augment therapeutic options for neuro-oncology patients. The green signal follows rigorous evaluation of clinical data and safety protocols. With rising incidence of brain tumours and limited existing treatments, this endorsement may not only improve patient outcomes, but also reshape India’s oncology-drug market, stimulating further innovation and competition in cancer therapy.

Cipla has unveiled a novel therapeutic agent, Yurpeak, targeting obesity and type-2 diabetes, reflecting the company’s commitment to addressing dual metabolic burdens. Positioned as a treatment to manage weight and glycemic control concurrently, the drug is poised to tap into India’s growing demand for integrated metabolic-health solutions. With rising prevalence of lifestyle disorders, Cipla’s release of Yurpeak could mark a significant milestone in the domestic pharmaceutical landscape — offering patients a fresh option while intensifying competition among diabetes care providers.

Torrent Pharmaceuticals, a leading Indian pharmaceutical company, has been levied a Rs 41 crore penalty for Goods and Services Tax (GST) non-compliance. The penalty follows a government review of tax filings and regulatory adherence, highlighting the importance of rigorous compliance in India’s heavily regulated pharmaceutical sector. Torrent Pharma, which operates across domestic and international markets, is expected to address the discrepancies promptly to avoid further legal and financial implications.

Cipla, a leading Indian pharmaceutical company, has inaugurated a state-of-the-art Lung Health Diagnostics Center, aiming to enhance early detection and management of respiratory diseases across India. The center integrates advanced diagnostic technologies and clinical expertise to provide comprehensive lung health assessments, targeting conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary infections.

Indian pharmaceutical major Zydus has secured approval from the US Food and Drug Administration for its latest diabetes treatment — a significant achievement that positions the company as a stronger contender in the global diabetes-care market. The green light from the US regulator validates the safety and efficacy profile of the drug and paves the way for its launch in the lucrative United States market. For Zydus, this approval represents not only a commercial breakthrough, but also a validation of its research and development capabilities.

Glenmark Pharmaceuticals has launched a new triple therapy treatment for Chronic Obstructive Pulmonary Disease (COPD) in India, targeting patients with moderate to severe respiratory conditions. The innovative therapy combines three active components in a single inhaler, offering enhanced symptom management, improved lung function, and simplified treatment adherence. This launch underscores Glenmark’s commitment to addressing chronic respiratory illnesses and expanding its presence in India’s growing specialty therapeutics segment.

Glenmark Pharmaceuticals reported a sharp 72% surge in its second-quarter profit, driven primarily by a milestone payment from its strategic licensing agreement with U.S.-based biopharmaceutical major AbbVie. The strong quarterly showing underscores the company’s ability to monetize its research pipeline while strengthening its financial position through partnerships that enhance global market access. Improved profitability comes at a crucial time for India’s pharmaceutical sector, which continues to focus on innovation-led growth and regulatory compliance.

Dr. Reddy’s Laboratories Ltd. reported a 14% year-on-year rise in net profit to Rs. 1,437 crore for the quarter ended September 2025, driven by robust sales in the U.S. generics market and steady growth in India. The pharmaceutical major benefited from a strong product mix, operational efficiency, and cost discipline, which offset pricing pressures in select markets. Revenue grew steadily across key geographies, while new product launches and a healthy pipeline strengthened its competitive position. With consistent performance and strategic focus on innovation, Dr.

Indian pharmaceutical major Lupin Ltd. has announced plans to invest USD 250 million in establishing a new manufacturing facility in the United States, marking a major step in its global expansion strategy. The move aims to strengthen Lupin’s presence in the world’s largest pharmaceutical market and enhance its production capabilities in complex generics and specialty products. The facility will cater to both domestic and export markets, reinforcing the company’s commitment to quality manufacturing, innovation, and compliance with global regulatory standards.

Torrent Pharmaceuticals has received demand notices totaling Rs. 6.63 crore from India’s National Pharmaceutical Pricing Authority (NPPA) for alleged overpricing of five drug formulations between January 2016 and November 2018. The notices, issued under Paragraph 15 of the Drug Price Control Order (DPCO) 2013, require the company to refund the purported excess amount charged.